Lynparza With Abiraterone Improves rPFS for Men with mCRPC

The PROpel phase 3 trial met the primary endpoints of radiographic progressing-free for men with metastatic castration-resistant prostate when treated with Olaparib, combined with abiraterone.

Olaparib (Lynparza, AstraZeneca, MSD) combined with abiraterone, showed improvement in radiographic progressing-free survival (rPFS) compared with standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair gene mutations, results from a phase 3 trial show.

“These exciting results demonstrate the potential for Lynparza with abiraterone to become a new first-line option for patients regardless of their biomarker status and reach a broad population of patients living with this aggressive disease. We look forward to discussing the results with global health authorities as soon as possible,” Susan Galbraith, PhD, executive vice president of Oncology R&D, said in a statement.

The PROpel phase 3 trial met the primary endpoints of rPFS in men with mCRPC who had not received first-line treatment with new hormonal agents or chemotherapy.

“We are encouraged by the PROpel results and the clinical benefit Lynparza in combination with abiraterone demonstrated versus abiraterone alone as a 1st-line treatment option for men with metastatic castration-resistant prostate cancer.

Today’s results build on MSD and AstraZeneca’s commitment to bring Lynparza earlier in lines of treatment and to more patients with advanced prostate cancer,” Roy Baynes, senior vice president and head of global clinical development at MSD Research Laboratories, said in the statement.

The study results showed a trend toward overall survival (OS), but the data are still new, so the trial will continue to assess OS as a secondary endpoint.

The safety and tolerability were consistent with the profiles of each medication.

Reference

Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer. AstraZeneca. News release. September 24, 2021. Accessed on October 11, 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-propel-trial-meets-primary-endpoint.html